RxDoctor Payments Data

Enoch Ulmer, MD

Family Medicine · Spartanburg, SCNPI 1598708133

Payments from drug & device makers

$1,434in general payments, 2019–2025

Across 65 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$190
  • AbbVie$162
  • Novo Nordisk$155
  • Abbott$137
  • Johnson & Johnson$108
  • Dexcom, Inc.$96
  • plus $587 from 19 others

What the payments were for

  • Food & beverage$1,434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,434 in reported general payments places this provider in the 65th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$38,459
Medicare patients
68
Services billed
2,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide31$31,988
EliquisApixaban18$15,063
JardianceEmpagliflozin12$12,851
InvokanaCanagliflozin13$8,185
Naproxen Sodium35$905
Rosuvastatin Calcium40$883
Fluoxetine Hcl22$773
Levothyroxine Sodium36$510
Pantoprazole Sodium31$503
Metoprolol Succinate18$490
Duloxetine Hcl38$444
Omeprazole36$403
Carvedilol23$375
Montelukast Sodium18$359
Amlodipine Besylate48$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$56$31,98831 claims
PfizerEliquis$21$15,06318 claims
Boehringer IngelheimJardiance$15$12,85112 claims
Johnson & JohnsonInvokana$108$8,18513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →